UA85377C2 - Use of composition containing hpv16 and hpv18 viral particles in preparation o medication for prevention of infection and/or desease caused by group of oncogenic hpv types, methods for inducing of immune reaction, prevention of infection and/or desease, prevention in subject population of infection caused by ome or more groups of oncogenic hpv types, vaccine composition containing hpv16 and нpv18 - Google Patents

Use of composition containing hpv16 and hpv18 viral particles in preparation o medication for prevention of infection and/or desease caused by group of oncogenic hpv types, methods for inducing of immune reaction, prevention of infection and/or desease, prevention in subject population of infection caused by ome or more groups of oncogenic hpv types, vaccine composition containing hpv16 and нpv18

Info

Publication number
UA85377C2
UA85377C2 UAA200505919A UA2005005919A UA85377C2 UA 85377 C2 UA85377 C2 UA 85377C2 UA A200505919 A UAA200505919 A UA A200505919A UA 2005005919 A UA2005005919 A UA 2005005919A UA 85377 C2 UA85377 C2 UA 85377C2
Authority
UA
Ukraine
Prior art keywords
prevention
infection
hpv types
composition containing
caused
Prior art date
Application number
UAA200505919A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ґері Дубин
Брюс Іннис
Монсеф Мохаммед Слауи
Мартин Анн Сесиль Веттендорфф
Original Assignee
Глаксосмітклайн Байолоджикалз Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмітклайн Байолоджикалз Са filed Critical Глаксосмітклайн Байолоджикалз Са
Publication of UA85377C2 publication Critical patent/UA85377C2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the use of a composition containing HPV16 and HPV18 viral paricles in preparation of a medication for prevention of infection and/or disease caused by the group of oncogenic HPV types as well to methods for inducing of immune reaction against one or more groups of oncogenic HPV types, prevention of infection and/or disease, caused by one or more groups of oncogenic HPV types, and prevention in the subject population of infection caused by one or more groups of oncogenic HPV types. The invention also relates to a vaccine composition containing HPV16 and HPV18 viral paricles and provides for cross protection against the infection and/or disease caused by the group of oncogenic HPV types.
UAA200505919A 2002-12-20 2003-12-18 Use of composition containing hpv16 and hpv18 viral particles in preparation o medication for prevention of infection and/or desease caused by group of oncogenic hpv types, methods for inducing of immune reaction, prevention of infection and/or desease, prevention in subject population of infection caused by ome or more groups of oncogenic hpv types, vaccine composition containing hpv16 and нpv18 UA85377C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
UA85377C2 true UA85377C2 (en) 2009-01-26

Family

ID=36166935

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505919A UA85377C2 (en) 2002-12-20 2003-12-18 Use of composition containing hpv16 and hpv18 viral particles in preparation o medication for prevention of infection and/or desease caused by group of oncogenic hpv types, methods for inducing of immune reaction, prevention of infection and/or desease, prevention in subject population of infection caused by ome or more groups of oncogenic hpv types, vaccine composition containing hpv16 and нpv18

Country Status (4)

Country Link
CN (1) CN100418577C (en)
SI (1) SI1572233T1 (en)
UA (1) UA85377C2 (en)
ZA (1) ZA200504907B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101116745B (en) * 2006-08-04 2011-05-11 长春百克生物科技股份公司 Human papilloma virus sample particle vaccines
CN101181636B (en) * 2006-11-14 2010-09-15 北京金迪克生物技术研究所 Compound vaccine composition for preventing and controlling human viral infection, compound vaccine vaginal mist and uses thereof
PL2444103T3 (en) * 2009-06-19 2018-05-30 Eyegene Inc. Vaccine for cervical cancer
CN102349996B (en) * 2011-10-17 2014-06-25 沈阳三生制药有限责任公司 Human papilloma virus pharmaceutical composition and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
ZA200504907B (en) 2006-08-30
CN1747745A (en) 2006-03-15
CN100418577C (en) 2008-09-17
SI1572233T1 (en) 2011-07-29

Similar Documents

Publication Publication Date Title
AP1872A (en) Virus-like particles of human papillomavirus.
MA33449B1 (en) RECOMBINANT ANTIGENS OF THE VRS
DE60024112D1 (en) INFLUENZA VIRUS VACCINE COMPOSITION
IL172189A0 (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
CY1112848T1 (en) SUSPENSION VIRUS INHIBITIONS C
HK1044799A1 (en) Immunoligically significant herpes simplex virus antigens
ZA200507178B (en) Optimized expression of HPV 31 L1 in yeast
NO965590D0 (en) Papillomavirus polynucleotide vaccine
EP2708549A3 (en) Improved vaccines and methods for using the same
WO2008019213A3 (en) Use of extracts for the treatment of viral disorders
WO2008092854A3 (en) Papillomavirus e2 polypeptide used for vaccination
GB2386072A (en) Novel vaccine
WO2002032942A3 (en) Compositions and methods for modulating rsv infection and immunity
MXPA02007271A (en) Pyrrole type compounds, compositions, and methods for treating cancer or viral diseases.
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
UA85377C2 (en) Use of composition containing hpv16 and hpv18 viral particles in preparation o medication for prevention of infection and/or desease caused by group of oncogenic hpv types, methods for inducing of immune reaction, prevention of infection and/or desease, prevention in subject population of infection caused by ome or more groups of oncogenic hpv types, vaccine composition containing hpv16 and нpv18
SG153837A1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
MXPA03009763A (en) Foot and mouth disease virus vaccine.
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
TW200509964A (en) VP1 of foot-and-mouth disease virus
EP1627663A3 (en) Use of a pharmaceutical composition for the treatment of pathologies derived from infection by herpes virus, papillomavirus, hepatitis virus, viral neuralgia, viral dsyplasia, immune-deficiency-induced viral infections and viral neuritis.
CA2562136A1 (en) Novel infectious bursal disease virus and vaccine containing said virus
MX2007013475A (en) Vaccine.